Literature DB >> 11929319

Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab.

Kazunao Kondo1, Kazuo Umemura.   

Abstract

Tirofiban is a nonpeptide tyrosine derivative that antagonises platelet glycoprotein IIb/IIIa (GP IIb/IIIa) receptors. It is one of three GP IIb/IIIa antagonists approved by the US Food and Drug Administration for the treatment of patients with acute coronary syndromes. The clinical effect of tirofiban has been shown in large studies such as PRISM (Platelet Receptor Inhibition for Ischemic Syndrome Management), PRISM-PLUS (PRISM - Patients Limited by Unstable Signs and Symptoms) and RESTORE (Randomised Efficacy Study of Tirofiban for Outcomes and Restenosis). Tirofiban is administered as an intravenous infusion. Volume of distribution ranges from 21 to 87 L, and binding to human plasma proteins is modest at 64%. Metabolism in humans is negligible, and most drug is excreted renally with systemic clearance ranging from 4.8 to 25.8 L/h. Renal function may influence the excretion of tirofiban, but concurrent disease or other drugs generally used in patients with ischaemia seem not to do so. This review updates what is known about the pharmacokinetics of tirofiban in humans, especially in comparison with the monoclonal antibody against the IIb/IIIa receptor, abciximab.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11929319     DOI： 10.2165/00003088-200241030-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


  41 in total

1.  Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.

Authors:  E J Topol; J J Ferguson; H F Weisman; J E Tcheng; S G Ellis; N S Kleiman; R J Ivanhoe; A L Wang; D P Miller; K M Anderson; R M Califf
Journal:  JAMA       Date:  1997-08-13       Impact factor: 56.272

2.  Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.

Authors:  M Cohen; P Théroux; S Weber; P Laramée; T Huynh; S Borzak; J G Diodati; I B Squire; L I Deckelbaum; A R Thornton; K E Harris; F L Sax; M W Lo; H D White
Journal:  Int J Cardiol       Date:  1999-12-01       Impact factor: 4.164

Review 3.  Safe use of platelet GP IIb/IIIa inhibitors.

Authors:  J J Ferguson; D J Kereiakes; A A Adgey; K A Fox; W B Hillegass; M Pfisterer; C Vassanelli
Journal:  Eur Heart J       Date:  1998-04       Impact factor: 29.983

4.  Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.

Authors:  M A Mascelli; E T Lance; L Damaraju; C L Wagner; H F Weisman; R E Jordan
Journal:  Circulation       Date:  1998-05-05       Impact factor: 29.690

5.  Determination of MK-383, a non-peptide fibrinogen receptor antagonist, in human plasma and urine by radioimmunoassay.

Authors:  E L Hand; J D Gilbert; A S Yuan; T V Olah; M Hichens
Journal:  J Pharm Biomed Anal       Date:  1994-08       Impact factor: 3.935

6.  Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention.

Authors:  S R Steinhubl; K Kottke-Marchant; D J Moliterno; M L Rosenthal; N K Godfrey; B S Coller; E J Topol; A M Lincoff
Journal:  Circulation       Date:  1999-11-09       Impact factor: 29.690

7.  Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins.

Authors:  S H Tam; P M Sassoli; R E Jordan; M T Nakada
Journal:  Circulation       Date:  1998-09-15       Impact factor: 29.690

8.  Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban.

Authors:  K Umemura; K Kondo; Y Ikeda; M Nakashima
Journal:  Thromb Haemost       Date:  1997-11       Impact factor: 5.249

9.  Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

Authors:  S J Brener; L A Barr; J E Burchenal; S Katz; B S George; A A Jones; E D Cohen; P C Gainey; H J White; H B Cheek; J W Moses; D J Moliterno; M B Effron; E J Topol
Journal:  Circulation       Date:  1998-08-25       Impact factor: 29.690

10.  Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.

Authors:  N S Kleiman; A E Raizner; R Jordan; A L Wang; D Norton; K F Mace; A Joshi; B S Coller; H F Weisman
Journal:  J Am Coll Cardiol       Date:  1995-12       Impact factor: 24.094
View more
  9 in total

Review 1.  Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions.

Authors:  H Benjamin Starnes; Ankit A Patel; George A Stouffer
Journal:  Drugs       Date:  2011-10-22       Impact factor: 9.546

Review 2.  Pharmacology of antiplatelet agents.

Authors:  Kiran Kalra; Christopher J Franzese; Martin G Gesheff; Eli I Lev; Shachi Pandya; Kevin P Bliden; Udaya S Tantry; Paul A Gurbel
Journal:  Curr Atheroscler Rep       Date:  2013-12       Impact factor: 5.113

3.  The Safety and Efficacy of Continuous Tirofiban as a Monoantiplatelet Therapy in the Management of Ruptured Aneurysms Treated Using Stent-Assisted Coiling or Flow Diversion and Requiring Ventricular Drainage.

Authors:  Kaustubh Limaye; Mario Zanaty; Joseph Hudson; Daichi Nakagawa; Sami Al Kasab; Carlos Alvarez; Sudeepta Dandapat; David K Kung; Santiago Ortega-Gutierrez; Pascal Jabbour; Edgar A Samaniego; David Hasan
Journal:  Neurosurgery       Date:  2019-12-01       Impact factor: 4.654

Review 4.  Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia: diagnosis and treatment.

Authors:  S M Said; J Hahn; E Schleyer; M Müller; G M Fiedler; M Buerke; R Prondzinsky
Journal:  Clin Res Cardiol       Date:  2006-12-08       Impact factor: 5.460

5.  Vanishing platelets: rapid and extreme tirofiban-induced thrombocytopenia after percutaneous coronary intervention for acute myocardial infarction.

Authors:  Nasir Rahman; Fahim H Jafary
Journal:  Tex Heart Inst J       Date:  2010

6.  Platelet aggregation pathway.

Authors:  Katrin Sangkuhl; Alan R Shuldiner; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-08       Impact factor: 2.089

Review 7.  Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review.

Authors:  Omer Celal Elcioglu; Abdullah Ozkok; Timur Selcuk Akpınar; Fatih Tufan; Murat Sezer; Sabahattin Umman; Sevgi Kalayoglu Besısık
Journal:  Int J Hematol       Date:  2012-07-06       Impact factor: 2.490

8.  The blocking effect of the glycoprotein IIb/IIIa receptor in the mouse model of asthma.

Authors:  Seo-Hee Kim; Hoang Kim Tu Trinh; Hae-Sim Park; Yoo Seob Shin
Journal:  Clin Mol Allergy       Date:  2021-07-13

9.  Stent-Assisted Coil Embolization Using Only a Glycoprotein IIb/IIIa Inhibitor (Tirofiban) for Ruptured Wide-Necked Aneurysm Repair.

Authors:  Sang Hyub Lee; In Sung Park; Ja Myoung Lee; Kwangho Lee; Hyun Park; Chul Hee Lee
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2018-03-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.